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Abstract: A series of cyclopeptoid-based iminosugar clus-
ters has been evaluated to finely probe the ligand con-
tent-dependent increase in a-mannosidase inhibition. This
study led to the largest binding enhancement ever report-
ed for an enzyme inhibitor (up to 4700-fold on a valency-
corrected basis), which represents a substantial advance
over the multivalent glycosidase inhibitors previously re-
ported. Electron microscopy imaging and analytical data
support, for the best multivalent effects, the formation of
a strong chelate complex in which two mannosidase mol-
ecules are cross-linked by one inhibitor.
Multivalency is intuitively recognized by chemists as an appeal-
ing strategy for the design of ligands displaying high binding
specificity for their receptors.[1] Emblematic examples are
found in cells where many key intercellular recognitions events
are mediated by multisite carbohydrate-binding proteins (lec-
tins), despite the fact that carbohydrate–lectin interactions are
individually weak.[2] The over-amplification of binding affinity
beyond that expected from a concentration increase is referred
to as the cluster or multivalent effect.[3] Inspired by Nature,
chemists have synthesized a large variety of glycoclusters ex-
hibiting impressive affinity enhancements over the correspond-
ing monovalent lectin ligands.[2,4] Much less effort has been di-
rected so far towards the design of multivalent inhibitors of
carbohydrate-processing enzymes despite their therapeutic
relevance. Enzymes appear a priori to be less suited for multi-
valent design since they usually display a single substrate bind-
ing site, rendering theoretically impossible chelation mecha-
nisms at the origin of the largest multivalent effects reported
for proteins.[2b,5] Very recently, the field has experienced
a major breakthrough with the discovery of the first strong
multivalent effects in glycosidase inhibition observed with imi-
nosugar clusters such as 1 bearing up to 21 DNJ (1-deoxynojir-
imycin) ligands (Figure 1).[6–10]
One of the next, forward-looking steps is to explore the
maximum level of affinity enhancement achievable through in-
hibitory multivalent effects. Beyond breaking new records,
identifying such limits, as well as the existence of a plateau[11]
in the valency-dependent affinity increase, is expected to shed
light on the molecular basis of this recently discovered effect.
Our strategy to tackle these objectives was based on iminosu-
gar clusters constructed on large cyclopeptoid cores with in-
crementally increasing valencies. The challenge of synthesizing
large multivalent iminosugars was addressed using a highly
convergent strategy based on CuI-catalyzed azide–alkyne cy-
cloaddition reactions (CuAAC). In this approach, the initial va-
lency of the polyalkyne scaffolds is tripled by the direct graft-
ing of azido-armed trivalent iminosugar dendrons
(Scheme 1).[10] Cyclopeptoids[12] appear as ideal tools to both
push and precisely probe the limits of multivalent effects.[12,13]
In contrast to most scaffolds, they indeed offer synthetic flexi-
bility, allowing the access to clusters with finely incremented
valencies.[14,15] Another challenge associated with high-valency
systems is that steric crowding of neighboring ligands may
limit the multivalent glycosidase binding.[10,11,16] This effect was
expected to be overcome by the fact that, in the designed cy-
clopeptoid-based clusters, the scaffold size grows with the va-
lency (Scheme 1).
To systematically increase valency in six ligand increments,
azido-armed trivalent iminosugar 4 was attached by CuAAC
onto a series of cyclopeptoids 5 bearing 6 to 16 propargyl
groups (Scheme 1). These scaffolds were efficiently prepared
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by way of iterative submonomer solid-phase synthesis fol-
lowed by cyclization in high dilution conditions, leading to
ones of the largest cyclopeptoids prepared by head-to-tail cou-
pling strategy (Scheme S3 in the Supporting Information).[13,17]
The decisive microwave-assisted CuAAC reaction was found to
proceed smoothly to provide the desired 18- to 48-valent pera-
cetylated DNJ clusters 6 in 32 to 77% yields which were depro-
tected by using basic anion exchange resin. These compounds
were evaluated as inhibitors of Jack bean a-mannosidase (JBa-
man), the glycosidase which has shown the largest responses
to multivalent inhibitor presentation to date.[8] The correspond-
ing inhibition constants (Ki) as well as relative inhibition poten-
cy (rp) over monovalent control 2a and valency-corrected rp
(rp/n) are collected in Table 1. Due to the structure of neogly-
coclusters 7 based on identical trivalent iminosugar subunits,
the inhibition potency of trivalent model 2b, obtained by
CuAAC coupling between 4 and ethynylcyclopropane, has
been determined (Scheme S1 in the Supporting Information
and Table 1).
In a previous study,[13] we have shown that 6- to 10-valent
cyclopeptoid-based DNJ clusters 3a–c (Figure 1) displayed
modest inhibitory multivalent effects (rp/n 3–4). The addition
of eight DNJ units, from 3c to 7a, led to a dramatic improve-
ment in binding enhancements to reach a rp/n value of 74. To
determine more precisely from which valency significant multi-
valent effects start to occur, 14-valent iminosugar 3d was pre-
pared (Scheme S2 in the Supporting Information). The submi-
cromolar Ki value for a-mannosidase inhibition obtained for
3d showed that a take-off in the multivalent effect could be
obtained by the addition of only four DNJ units, from 10 to 14
(Table 1). Remarkably, the rp/n values measured for valency
from 6 to 36 were found to fit an exponential curve with an as-
tonishing high correlation (Figure S1 in the Supporting Infor-
mation). The 36-valent cluster 7d was found to display an out-
standing relative inhibition potency of about 171000-fold, far
from the ones previously observed for clusters 1—the previous
standards in the field (4750-fold vs. 610-fold in a valency-cor-
rected basis).[7, 8, 10] Beyond glycosidase inhibition, cluster 7d[18]
provides, to our knowledge, the largest binding enhancements
ever reported for an enzyme inhibitor.[19,20] Further increasing
the number of DNJ ligands (from 36 to 48) did not enhance
the inhibitory potency of iminosugar clusters 7, leading clearly
to a plateau in terms of Ki values. To obtain insights into the
binding modes underlying the outstandingly large multivalent
effect observed, a mechanistic study using three different com-
plementary techniques was performed. The interactions of
JBa-man with 7d were first analyzed using electron microsco-
py (EM) with negative staining (Figure 2). JBa-man is a high-
molecular-weight metalloenzyme organized into a homodimer
(LH)2 of active heterodimers (LH for light and heavy chains) of
approximately 66 (H) and about 44 kDa (L), respectively.[21] In
Figure 1. Multi- and monovalent inhibitors of JBa-man.
Table 1. Relative inhibition potencies of iminosugar clusters and inhibito-
ry activities (Ki [mm]) against JBa-man.
[6, 7, 10,13]
Cpd DNJ unit Ki
[a] rp[b] rp/n[c]
2a[6] 1 188[6] – –
2b 3 10.51.5 18 6
1b[10] 21 0.0190.003[10] 9895 471
3c[13] 10 51[13] 38 3.8
3d 14 0.1260.014 1492 107
7a 18 0.1420.017 1324 74
7b 24 0.0370.012 5081 212
7c 30 0.00990.0028 18990 633
7d 36 0.00110.0004 170909 4747
7e 42 0.00150.0003 125333 2984
7 f 48 0.00110.00007 170909 3560
[a] Means SD obtained from experiments performed in triplicate.
[b] Relative inhibition potency=Ki (monovalent reference 2a)/Ki(cluster).
[c] rp/n= rp/number of DNJ units.
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the case of the mannosidase alone, the image showed clear
clusters of approximately 10Õ20 nm (Figure 2, left, light-col-
ored frame) matching the size of one homodimer (LH)2.
For the complex of JBa-man with 7d, several different ar-
rangements are seen, including some approximately 20Õ
20 nm in size that may correspond to the interaction of one in-
hibitor with two tetramers (LH)2 (Figure 2, right, dark-colored
frame). This hypothesis was confirmed by analytical ultracentri-
fugation sedimentation velocity (AUC-SV) experiments
(Figure 3).[22]
For JBa-man alone, the main sedimenting species is ob-
served at 9.3 S, corresponding to the tetramer (LH)2 with
a molar mass estimate of 210 kDa (see the Supporting informa-
tion).[23] The sedimentation coefficient distribution c(s) showed
also a minor species with a sedimentation coefficient value of
13.4 S which may correspond to the association of two JBa-
man molecules in a 2Õ (LH)2 complex. The binding of JBa-man
to 7d created a broader sedimentation coefficient distribution
Scheme 1. Reagents and conditions : synthesis of DNJ clusters 7: a) CuSO4·5H2O cat. , sodium ascorbate, DMF/H2O (5:1), MW, 80 8C or 90 8C; 6a (m=1) 75%;
6b (m=3) 73%; 6c (m=5) 53%; 6d (m=7) 70%; 6e (m=9) 77%; 6 f (m=11) 32%. b) Amberlite (OH¢), MeOH/H2O (1:1), 40 8C; 7a (m=1) 88%; 7b (m=3)
77%; 7c (m=5) quant. ; 7d (m=7) 57%; 7e (m=9) 81%; 7 f (m=11) 85%.
Figure 2. EM pictures of JBa-man (left) and JBa-man interacting with 7d
(right) ; scale bars=50 nm.
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exhibiting maxima at about 14 S, suggesting the reversible for-
mation of a 2:1 tetramer(LH)2–inhibitor complex in dynamic
equilibrium with other species. AUC-SV control experiments
were also performed with a system displaying a small multiva-
lent effect (DNJ cluster 3b, rp/n ~3) or for which the binding
stoichiometry had been previously determined to be close to
one by isothermal titration calorimetry (1c).[24] In both cases,
the major species observed corresponded to the (LH)2–inhibi-
tor 1:1 complex whereas for the larger cluster 7a, with a rp/n
value of 74, the equilibrium is clearly in favor of the 2:1 (LH)2–
inhibitor complex (Figure S3 in the Supporting Information).
Native electrospray mass spectrometry (ESI-MS) was performed
to further confirm the stoichiometry of the noncovalent macro-
molecular enzyme–inhibitor complex (Figure 4).[25] MS obtained
on the native enzyme before and after the inhibitor addition
showed the presence of three different multicharged ions pat-
terns (Figure 4). When JBa-man is alone in the solution studied
(Figure 4a), the molecular masses measured correspond to the
primal heterodimer LH (MW=121.3 kDa), the tetramer (LH)2
(MW=242.3 kDa) and the association of two tetramers (LH)2
(MW=484.9 kDa), respectively (see the Supporting information).
After addition of the inhibitor 7d (MW=17.4 kDa, Figure 4b),
both enzyme–inhibitor complexes are observed with a 17 kDa
shift (MW=259.9 kDa for the 1:1 complex and MW=501.9 kDa
for the 2:1 complex).
Based on the corroborating results obtained with three dif-
ferent techniques, the outstanding multivalent effects ob-
served may be rationalized by the formation of a strong che-
late complex in which the inhibitor cross-links two tetramers
(LH)2 (Figure 5). Such a complex would involve reversible
active-site specific interactions but also protein–protein inter-
actions between two tetramers. Increasing the valency and the
global size of the scaffold shifts the equilibrium of the different
Figure 3. The top panel shows the sedimentation coefficient distribution
plot for JBa-man (solid line) and for the JBa-man:7d complex (dotted line).
The bottom panel shows the same distributions normalized to a maximum
of 1.0.
Figure 4. Native ESI-MS spectra for : a) JBa-man, and b) JBa-man interacting with 7d. Multicharged ions patterns are labeled with the corresponding enzyme
and enzyme–inhibitor complexes.
Chem. Eur. J. 2016, 22, 5151 – 5155 www.chemeurj.org Ó 2016 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim5154
Communication
species in solution towards the 2:1 tetramer–inhibitor complex
even in the presence of an excess of inhibitor showing that
the 2:1 sandwich may be thermodynamically favored. The im-
plications of these findings for the design of multivalent inhibi-
tors and the identification from the protein data bank of other
multimeric glycosidases responsive to multivalency are current-
ly under investigation in our laboratories.
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Figure 5. Cartoon representation of a large reversible multivalent inhibitor
forming chelate complexes with JBa-man.
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